Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Ventus Therapeutics Initiates Clinical Testing of VENT-03
Ventus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference
Ventus Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today that the company’s Head of Platform Technologies, Jason Burch, Ph.D., will give an oral presentation on ReSOLVE™, Ventus’ proprietary drug discovery platform, at the Canadian Chemistry Conference and Exhibition (CSC) 2023, being held on June 4-8, 2023 in Vancouver, British Columbia.
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today that it will host its inaugural Program Spotlight on VENT-03 on May 25th, 2023 at 11:00 AM ET.
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today that it has been awarded a $150,000 grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Initiated in 2022, MJFF’s Novel PET Tracer Development Program supports work to develop and validate positron emission tomography (PET) imaging techniques utilizing radiotracers of targets relevant to Parkinson’s disease, such as NLRP3, for potential use as a diagnostic tool, for risk assessment, or as a surrogate biomarker to monitor disease progression and efficacy of therapies.
Ventus Therapeutics Provides Updates on cGAS Inhibitor Program at Keystone Symposium on Innate Immunity